SI1228071T1 - Farmacevtsko aktivni izoindolinovi derivati - Google Patents

Farmacevtsko aktivni izoindolinovi derivati

Info

Publication number
SI1228071T1
SI1228071T1 SI200030951T SI200030951T SI1228071T1 SI 1228071 T1 SI1228071 T1 SI 1228071T1 SI 200030951 T SI200030951 T SI 200030951T SI 200030951 T SI200030951 T SI 200030951T SI 1228071 T1 SI1228071 T1 SI 1228071T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutically active
isoindoline derivatives
active isoindoline
derivatives
oxoisoindoline
Prior art date
Application number
SI200030951T
Other languages
English (en)
Inventor
Hon-Wah Man
George Muller
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SI1228071T1 publication Critical patent/SI1228071T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200030951T 1999-11-12 2000-11-09 Farmacevtsko aktivni izoindolinovi derivati SI1228071T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16516899P 1999-11-12 1999-11-12
US59034400A 2000-06-08 2000-06-08
US09/708,199 US6667316B1 (en) 1999-11-12 2000-11-08 Pharmaceutically active isoindoline derivatives
PCT/US2000/030770 WO2001034606A1 (en) 1999-11-12 2000-11-09 Pharmaceutically active isoindoline derivatives
EP00977095A EP1228071B8 (en) 1999-11-12 2000-11-09 Pharmaceutically active isoindoline derivatives

Publications (1)

Publication Number Publication Date
SI1228071T1 true SI1228071T1 (sl) 2007-08-31

Family

ID=27389110

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030951T SI1228071T1 (sl) 1999-11-12 2000-11-09 Farmacevtsko aktivni izoindolinovi derivati

Country Status (19)

Country Link
US (1) US6667316B1 (sl)
EP (4) EP2263669B1 (sl)
JP (1) JP5116201B2 (sl)
CN (1) CN1325497C (sl)
AT (4) ATE544452T1 (sl)
AU (2) AU782409B2 (sl)
CA (1) CA2392081C (sl)
CY (2) CY1107610T1 (sl)
DE (1) DE60034139T2 (sl)
DK (2) DK2263669T3 (sl)
ES (4) ES2363933T3 (sl)
FI (1) FI119931B (sl)
HK (2) HK1049158A1 (sl)
MX (1) MXPA02004793A (sl)
NO (2) NO323633B1 (sl)
NZ (1) NZ519459A (sl)
PT (2) PT1228071E (sl)
SI (1) SI1228071T1 (sl)
WO (1) WO2001034606A1 (sl)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
WO1998006692A1 (en) * 1996-08-12 1998-02-19 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
US8030343B2 (en) * 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7491634B2 (en) * 2006-04-28 2009-02-17 Asm International N.V. Methods for forming roughened surfaces and applications thereof
AU2002257195A1 (en) 2001-04-23 2002-11-05 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
AU2002323063B2 (en) * 2001-08-06 2007-11-08 Entremed, Inc. Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
NZ570777A (en) * 2002-05-17 2009-04-30 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
NZ539534A (en) 2002-10-15 2008-06-30 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
NZ540185A (en) * 2002-10-31 2008-01-31 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
AU2003290652B2 (en) * 2002-11-06 2008-06-19 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
KR20050072790A (ko) * 2002-11-06 2005-07-12 셀진 코포레이션 골수증식 질환의 치료 및 관리를 위한 선택적 시토킨 억제약물의 사용 방법 및 이를 포함하는 조성물
BR0316259A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
EP1587474B1 (en) 2002-12-30 2009-11-18 Celgene Corporation Fluoroalkoxy-substituted 1, 3-dihydro-isoindolyl compounds and their pharmaceutical uses
JP2006519875A (ja) * 2003-03-06 2006-08-31 セルジーン・コーポレーション 中枢神経系障害を治療するための選択的サイトカイン阻害剤
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
ES2436606T3 (es) * 2003-03-12 2014-01-03 Celgene Corporation Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
CN100427465C (zh) * 2003-03-12 2008-10-22 细胞基因公司 N-烷基-异羟肟酸-异吲哚基化合物及其药物用途
KR101138064B1 (ko) * 2003-03-12 2012-04-23 셀진 코포레이션 Ｎ-알킬-히드록삼산-이소인돌릴 화합물 및 그의 제약학적용도
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2543132A1 (en) * 2003-10-23 2005-05-19 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
CN1972686A (zh) * 2004-04-14 2007-05-30 细胞基因公司 选择性细胞因子抑制药在髓发育不良综合征中的用途
JP2007533760A (ja) * 2004-04-23 2007-11-22 セルジーン・コーポレーション 肺高血圧症を治療し管理するための、ｐｄｅ４モジュレーターの使用方法及びｐｄｅ４モジュレーターを含む組成物
BRPI0418800A (pt) * 2004-05-05 2007-10-16 Celgene Corp métodos de tratamento ou prevenção, e de controle, de uma doença mieloproliferativa, de redução ou prevenção de um efeito adverso, de aumento da eficácia terapêutica de um tratamento de doença mieloproliferativa, composição farmacêutica, e, kit
MXPA06012698A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodos y composiciones que utilizan farmacos inhibidores de citocina selectiva para el tratamiento y manejo de canceres y otras enfermedades.
WO2006004191A1 (en) * 2004-07-05 2006-01-12 Astellas Pharma Inc. Pyrrolopyridazine derivatives which inhibit pde iv and tnf alfa
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
WO2006028963A2 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
WO2006065814A1 (en) * 2004-12-13 2006-06-22 Celgene Corporation Compositions comprising pde4 modulators and their use for the treatment or prevention of airway inflammation
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
CN102036663A (zh) * 2008-03-24 2011-04-27 细胞基因公司 用环丙基-n-{2-[(1s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲磺酰基)乙基]-3-氧代异吲哚啉-4基}甲酰胺治疗银屑病或者银屑病关节炎
AU2009298888A1 (en) 2008-09-23 2010-04-08 Georgetown University 1,2-benzisothiazolinone and isoindolinone derivatives
US8563580B2 (en) 2008-09-23 2013-10-22 Georgetown University Flavivirus inhibitors and methods for their use
WO2010093588A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
CN107964016B (zh) * 2009-05-14 2021-10-01 天津合美医药科技有限公司 噻吩衍生物
EA021019B1 (ru) 2009-06-18 2015-03-31 Концерт Фармасьютикалс, Инк. Дейтерированные производные изоиндолин-1,3-диона
RU2557236C2 (ru) * 2009-10-09 2015-07-20 Селджин Корпорейшн Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
CA2783616A1 (en) * 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
CA2794096A1 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
CN103026229B (zh) 2010-06-15 2016-03-30 细胞基因公司 用于治疗银屑病的生物标志物
ES2673114T3 (es) * 2011-01-10 2018-06-19 Celgene Corporation Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
EP2663292B9 (en) 2011-01-10 2017-11-08 Celgene Corporation Oral dosage forms of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl]-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
CA2845551C (en) 2011-08-16 2020-06-09 Georgetown University Methods of treating bacterial infections with 1,2-benzisothiazolinone and isoindolinone derivatives
US9884042B2 (en) * 2011-09-14 2018-02-06 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
EP3157520B1 (en) 2014-06-23 2019-09-04 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN107635962A (zh) * 2015-03-19 2018-01-26 印度商西伯拉有限公司 用于制备阿普斯特的改进工艺
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)
HU231259B1 (hu) 2016-02-04 2022-06-28 Egyt Gyogyszervegyeszeti Gyar Eljárás pomalidomide elõállítására
AU2017317123B9 (en) * 2016-08-22 2021-11-25 Medshine Discovery Inc. PDE4 inhibitor
CN107698484B (zh) * 2017-11-13 2020-05-19 广东中科药物研究有限公司 一种来那度胺的衍生物的制备方法与应用
WO2019142124A1 (en) 2018-01-17 2019-07-25 Cadila Healthcare Limited Pharmaceutical compositions for treatment of vitiligo
JP2021522315A (ja) 2018-04-17 2021-08-30 天津合美医▲薬▼科技有限公司Ｔｉａｎｊｉｎ Ｈｅｍａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． イソインドール誘導体
CN110746376B (zh) * 2018-07-22 2024-04-30 上海星叶医药科技有限公司 苯并异硒唑酮胺类化合物及其制备方法和用途
CN110003084B (zh) * 2019-03-15 2022-08-02 华南师范大学 一种同时具有力致发光和聚集诱导发光特性的有机圆偏振发光材料及其制备方法与应用
CN111170925B (zh) * 2020-01-09 2023-01-17 常州大学 作为pde2/4双重抑制剂的邻苯二甲酰亚胺类化合物及其制备方法
US20240124418A1 (en) * 2020-12-14 2024-04-18 Biotheryx, Inc. Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4173652A (en) 1976-12-18 1979-11-06 Akzona Incorporated Pharmaceutical hydroxamic acid compositions and uses thereof
SE434638B (sv) 1980-06-06 1984-08-06 Lekemedelsfabriken Medica Ab Nya terapeutiska verdefulla taurinderivat och deras framstellning
US4820828A (en) 1987-03-04 1989-04-11 Ortho Pharmaceutical Corporation Cinnamohydroxamic acids
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5605914A (en) 1993-07-02 1997-02-25 Celgene Corporation Imides
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5703098A (en) 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
MX9800710A (es) 1995-07-26 1998-04-30 Pfizer Derivados de n-(aroil) glicina acido hidroxamico y compuestos relacionados.
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
ES2217386T3 (es) 1996-01-02 2004-11-01 Aventis Pharmaceuticals Inc. Compuestos de acido(aril, heteroaril, arilmetil o heteroarilmetil) hidroxamico sustituido.
PL193829B1 (pl) * 1996-08-07 2007-03-30 Darwin Discovery Ltd Pochodne kwasów hydroksamowych, środek farmaceutyczny i zastosowanie pochodnych kwasów hydroksamowych w medycynie
WO1998006692A1 (en) 1996-08-12 1998-02-19 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
KR100716475B1 (ko) * 1997-07-31 2007-05-10 셀진 코오퍼레이션 치환된 알카노하이드록삼산 및 ＴＮＦα 농도 감소화 방법
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels

Also Published As

Publication number Publication date
PT1228071E (pt) 2007-05-31
JP2004500346A (ja) 2004-01-08
EP2255801A1 (en) 2010-12-01
EP2263669A1 (en) 2010-12-22
ES2381174T3 (es) 2012-05-23
CY1107610T1 (el) 2013-03-13
NO336210B1 (no) 2015-06-15
NO20071490L (no) 2002-07-08
DE60034139D1 (de) 2007-05-10
HK1053467A1 (en) 2003-10-24
EP1698334A1 (en) 2006-09-06
US6667316B1 (en) 2003-12-23
EP1228071A1 (en) 2002-08-07
NO20022223D0 (no) 2002-05-08
JP5116201B2 (ja) 2013-01-09
ATE544452T1 (de) 2012-02-15
EP1228071A4 (en) 2002-12-04
AU2005202964A1 (en) 2005-08-11
CA2392081C (en) 2010-01-05
DK2263669T3 (da) 2012-04-23
EP2263669B1 (en) 2012-02-08
FI20020892A (fi) 2002-06-20
HK1049158A1 (zh) 2003-05-02
DK1228071T3 (da) 2007-08-06
ES2282147T3 (es) 2007-10-16
ES2380574T3 (es) 2012-05-16
AU782409B2 (en) 2005-07-28
FI20020892A0 (fi) 2002-05-10
EP1228071B1 (en) 2007-03-28
CY1112707T1 (el) 2016-02-10
DE60034139T2 (de) 2007-12-06
CA2392081A1 (en) 2001-05-17
WO2001034606A1 (en) 2001-05-17
NZ519459A (en) 2003-11-28
AU1478001A (en) 2001-06-06
PT2263669E (pt) 2012-04-23
FI119931B (fi) 2009-05-15
ATE506058T1 (de) 2011-05-15
CN1420889A (zh) 2003-05-28
NO323633B1 (no) 2007-06-18
AU2005202964B2 (en) 2007-11-22
EP1698334B1 (en) 2011-04-20
NO20022223L (no) 2002-07-08
EP1228071B8 (en) 2012-02-29
MXPA02004793A (es) 2003-10-14
EP2255801B1 (en) 2012-02-08
ATE357913T1 (de) 2007-04-15
CN1325497C (zh) 2007-07-11
ES2363933T3 (es) 2011-08-19
ATE544451T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
HK1053467A1 (en) Pharmaceutically active isoindoline derivatives
ATE317845T1 (de) Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
ZA200201509B (en) Pharmaceutically active sulfonamide derivatives.
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
EP1295611A4 (en) COMPOUNDS FOR THE TRANSFER OF OLIGONUCLEOTIDES (03.01.02)
IL142581A (en) Medicament for treating heart disease
ZA9811154B (en) (E)-3-(1-n-butyl-5-(2-(2-carboxyphenyl)methoxy-4-chlorophenyl)-1H-pyrazol-4-yl)-2-((5-methoxy-2,3-dihydrobenzo-furan-6-yl)methyl)-prop-2-enoic acid monoarginilyn salt
SE9902742D0 (sv) New pharmaceutical formultion
AU7568500A (en) Laser probe for medical treatment
ITMO990002A0 (it) Articolatore per odontotecnica.
WO2002024210A3 (en) Halogen compounds for use in medicine
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
AU4506301A (en) Dynamic parity inversion for i/o interconnects
EP1210949A4 (en) Anti-ulcer agents
RU2000106182A (ru) Средство для лечения поражения кожи различной этиологии
RU98106825A (ru) Средство для лечения герпетических заболеваний глаз
IT247616Y1 (it) Bocchino monouso perfezionato, in particolare per narghile'.
ZA200005185B (en) Indole-2,3-Dione-3-Oxime derivatives for therapeutic use.
ES1042703Y (es) "cuadro perfeccionado".
RU2001111898A (ru) Способ повышения воспроизводительной способности хряков
ES1044269Y (es) Mesa camilla desmontable.